Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102242 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
A Phase 2 study, sponsored by Alliance Foundation Trials.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03102242 is a Phase 2 study that has completed, run by Alliance Foundation Trials. The registered enrollment target is 64 participants.
The verdict
NCT03102242, a Phase 2 study, has completed, sponsored by Alliance Foundation Trials.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102242
The ClinicalTrials.gov registry entry for NCT03102242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT03102242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03102242 about?
NCT03102242 is a clinical study titled "Atezolizumab Immunotherapy in Patients With Advanced NSCLC". Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
What is the current status of trial NCT03102242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-11-01. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT03102242?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03102242?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.